Literature DB >> 18840437

MicroRNA-183 regulates Ezrin expression in lung cancer cells.

Guofu Wang1, Weimin Mao, Shu Zheng.   

Abstract

Lung cancer is the leading cause of cancer death. However, the mechanism of lung cancer relapse and metastasis has been poorly elucidated. Recent researches have addressed the role of MicroRNAs (miRNAs) in mediating tumor metastasis. In the present study, we identified microRNA-183 (miR-183) as a potential metastasis-inhibitor. Expression level of miR-183 was reversely correlated with the metastatic potential of lung cancer cells. Furthermore, over-expression of miR-183 inhibited migration and invasion of lung cancer cells. Mechanistically, we identified VIL2-coding-protein Ezrin as a bona fide target of miR-183. We also found that miR-183 could regulate the expression of other genes involved in migration and invasion. Taken together, our findings demonstrated a new role and regulatory mechanism of miR-183 in controlling cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840437     DOI: 10.1016/j.febslet.2008.09.051

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  74 in total

1.  Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.

Authors:  Seyed H Ghaffari; Davood Bashash; Majid Zaki Dizaji; Ardeshir Ghavamzadeh; Kamran Alimoghaddam
Journal:  Tumour Biol       Date:  2011-11-10

2.  Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma.

Authors:  Shyamal Dilhan Weeraratne; Vladimir Amani; Natalia Teider; Jessica Pierre-Francois; Dominic Winter; Min Jeong Kye; Soma Sengupta; Tenley Archer; Marc Remke; Alfa H C Bai; Peter Warren; Stefan M Pfister; Judith A J Steen; Scott L Pomeroy; Yoon-Jae Cho
Journal:  Acta Neuropathol       Date:  2012-03-10       Impact factor: 17.088

3.  Upregulation of proapoptotic microRNA mir-125a after massive small bowel resection in rats.

Authors:  Anita Balakrishnan; Adam T Stearns; Peter J Park; Jonathan M Dreyfuss; Stanley W Ashley; David B Rhoads; Ali Tavakkolizadeh
Journal:  Ann Surg       Date:  2012-04       Impact factor: 12.969

Review 4.  microRNAs: tiny RNA molecules, huge driving forces to move the cell.

Authors:  Shenglin Huang; Xianghuo He
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

5.  MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma.

Authors:  Chenggang Wang; Ren Ren; Haolin Hu; Changjun Tan; Miao Han; Xiaolin Wang; Yun Zheng
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

6.  Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers.

Authors:  F Xu; H Zhang; Y Su; J Kong; H Yu; B Qian
Journal:  Clin Transl Oncol       Date:  2014-05-08       Impact factor: 3.405

7.  In silico method for systematic analysis of feature importance in microRNA-mRNA interactions.

Authors:  Jiamin Xiao; Yizhou Li; Kelong Wang; Zhining Wen; Menglong Li; Lifang Zhang; Xuanmin Guang
Journal:  BMC Bioinformatics       Date:  2009-12-16       Impact factor: 3.169

8.  MicroRNA-183 promotes migration and invasion of CD133(+)/CD326(+) lung adenocarcinoma initiating cells via PTPN4 inhibition.

Authors:  Conghui Zhu; Xi Deng; Jingbo Wu; Jianwen Zhang; Hongru Yang; Shaozhi Fu; Yan Zhang; Yunwei Han; Yuanmei Zou; Zhengtang Chen; Sheng Lin
Journal:  Tumour Biol       Date:  2016-03-07

9.  miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells.

Authors:  Jipeng Li; Hanjiang Fu; Chengwang Xu; Yi Tie; Ruiyun Xing; Jie Zhu; Yide Qin; Zhixian Sun; Xiaofei Zheng
Journal:  BMC Cancer       Date:  2010-07-06       Impact factor: 4.430

10.  Epidermal growth factor receptor-regulated miR-125a-5p--a metastatic inhibitor of lung cancer.

Authors:  Guofu Wang; Weimin Mao; Shu Zheng; Jingjia Ye
Journal:  FEBS J       Date:  2009-08-21       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.